Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:United_States_federal_law
|
| gptkbp:alsoKnownAs |
gptkb:Right_to_Try_law
|
| gptkbp:alternativeTo |
gptkb:FDA_expanded_access_program
|
| gptkbp:appliesTo |
investigational drugs
patients with life-threatening diseases |
| gptkbp:canBeBypassedBy |
FDA approval process
|
| gptkbp:category |
gptkb:2018_in_American_law
gptkb:Health_law gptkb:Medical_ethics |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:enactedBy |
gptkb:United_States_Congress
|
| https://www.w3.org/2000/01/rdf-schema#label |
Right to Try Act
|
| gptkbp:publicLawNumber |
115-176
|
| gptkbp:purpose |
allow terminally ill patients to access experimental treatments
|
| gptkbp:requires |
drug must have completed Phase I clinical trials
|
| gptkbp:signedBy |
gptkb:Donald_Trump
2018-05-30 |
| gptkbp:bfsParent |
gptkb:compassionate_use
|
| gptkbp:bfsLayer |
5
|